Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Matinas BioPharma (MTNB) Stock Price & Analysis
1,439 Followers
MTNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.11 - $0.89
Previous Close$0.17
Volume692.33K
Average Volume (3M)1.72M
Market Cap
$40.13M
Enterprise Value$27.50M
Total Cash (Recent Filing)$18.22M
Total Debt (Recent Filing)$3.71M
Price to Earnings (P/E)-1.6
Beta1.10
Next Earnings
Aug 07, 2024EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding250,816,164
10 Day Avg. Volume1,386,076
30 Day Avg. Volume1,723,805
Standard Deviation0.26
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.27
Price to Sales (P/S)13.18
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.74
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$0.80Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Matinas BioPharma News
Ownership Overview
12.66%
Insiders
4.35% Mutual Funds
6.92% Other Institutional Investors
76.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MTNB FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was $0.11 and its highest was $0.89 in the past 12 months.
What is Matinas BioPharma’s market cap?
Currently, no data Available
When is Matinas BioPharma’s upcoming earnings report date?
Matinas BioPharma’s upcoming earnings report date is Aug 07, 2024 which is in 78 days.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on May 09, 2024. The company reported -$0.03 earnings per share for the quarter, the consensus estimate of -$0.03 by $0.
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate is -$0.03.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 250,816,160 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -$0.03 in its last earnings report, expectations of -$0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in MTNB
---
Matinas BioPharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.80 (400.00% Upside)
$0.80 (400.00% Upside)
Blogger Sentiment
Bullish
MTNB Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.23%
12-Months-Change
Fundamentals
Return on Equity
-98.57%
Trailing 12-Months
Asset Growth
-48.75%
Trailing 12-Months
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
---
MTNB Earnings Call
Q1 2024
0:00 / 0:00
---
MTNB Stock 12 Month Forecast
Average Price Target
$0.80
▲(400.00% Upside)
Technical Analysis
Best Analysts Covering MTNB
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-47.53%
reiterated a buy rating 12 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.53% per trade.
---